| Literature DB >> 18166796 |
Henk M Lokhorst1, Ingo Schmidt-Wolf, Pieter Sonneveld, Bronno van der Holt, Hans Martin, Rene Barge, Uta Bertsch, Jana Schlenzka, Gerard M J Bos, Sandra Croockewit, Sonja Zweegman, Iris Breitkreutz, Iris Breitkreuz, Peter Joosten, Christof Scheid, Marinus van Marwijk-Kooy, Hans-Juergen Salwender, Marinus H J van Oers, Ron Schaafsma, Ralph Naumann, Harm Sinnige, Igor Blau, Michel Delforge, Gregor Verhoef, Okke de Weerdt, Pierre Wijermans, Shulamiet Wittebol, Ulrich Duersen, Edo Vellenga, Hartmut Goldschmidt.
Abstract
In the prospective phase 3 HOVON-50/GMMG-HD3 trial, patients randomized to TAD (thalidomide, doxorubicin, dexamethasone) had a significantly higher response rate (at least PR) after induction compared with patients randomized to VAD (vincristine, adriamycin, dexamethasone, 72% vs. 54%, p<0.001). Complete remission (CR) and very good partial remission (VGPR) were also higher after TAD. After High Dose melphalan 200mg/m(2) response was comparable in both arms, 76% and 79% respectively. However, CR plus VGPR were significantly higher in the patients randomized to TAD (49% vs. 32%, p<0.001). CTC grade 3-4 adverse events were similar in both arms.Entities:
Mesh：
Substances：
Year: 2008 PMID： 18166796 DOI： 10.3324/haematol.11644
Source DB: PubMed Journal: Haematologica ISSN： 0390-6078 Impact factor: 9.941